EYLEA® (Aflibercept) And Soliris® (Eculizumab) IPR

On December 8, 2023, the PTAB instituted three of Samsung Bioepis's pending IPRs against Alexion's Soliris® (eculizumab), IPR2023-00933, IPR2023-00998, and IPR2023-00999.

Related Keywords

United States , Frankfurt , Brandenburg , Germany , Stites Harbison , Kurnit Klein Selz , Reddy Laboratories Inc , Roche Inc , National Institute Of Standards , Biogen Inc , Goodwin Procter , Genentech Inc , Global Advertising Lawyers Alliance , Perkins Coie , Intellectual Property , National Institute , Advertising Lawyers Alliance , Hoffmann La Roche Inc , Mondaq , Eylea Xae Aflibercept And Soliris Eculizumab Ipr Updates , Food , Drugs , Healthcare , Life Sciences , Iotechnology Amp Nanotechnology , Patent , ,